Abivax SA

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax has filed proposed terms to raise $250 million in an IPO to fund the development of its treatment candidates for chronic inflammatory diseases. The company's lead candidate, Obefazimod, is entering Phase 3 clinical trials for Ulcerative Colitis and Phase 2 trials for Crohn's Disease. The global market for treatments for ulcerative colitis is expected to reach $10.25 billion by the end of 2027, providing a significant opportunity for Abivax.

Abivax Readies $250 Million U.S. IPO For Drug Pipeline

PARIS, FRANCE / ACCESSWIRE / October 16, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the start of its roadshow in connection with its intention to issue, subject to market and other conditions, 18,675,500 ordinary shares of the Company in an initial public offering of American Depositary Shares ("ADSs"), each representing one ordinary share, in the United States (the "U.S. Offering") and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the "European Private Placement", and together, the "Global Offering"). Abivax intends to grant the underwriters a 30-day option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.

Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

Birkenstock Holding Plc

Agape ATP Corp

Global Mofy Metaverse Ltd

Gamer Pakistan Inc

La Rosa Holdings Corp

Mach Natural Resources LP

Primech Holdings Ltd

Perfect Moment Ltd

Pheton Holdings Ltd

Five companies priced IPOs this week, led by Birkenstock's $1.5 billion offering. Three small issuers submitted initial filings. Birkenstock priced its IPO just below the midpoint to raise $1.5 billion at an $8.6 billion market cap, making it one of the largest consumer discretionary IPOs of the past two decades.

U.S. IPO Weekly Recap: Birkenstock Missteps In Public Debut

Abivax SA has filed for a $100 million IPO in the U.S. to raise funds for its pipeline development plans. The company's lead candidate, Obefazimod, is entering Phase 3 clinical trials for Ulcerative Colitis and Phase 2 trials for Crohn's Disease. The global market for treatments for ulcerative colitis is expected to exceed $10 billion by 2027, driving the growth of Abivax's products.

News for Abivax SA Stock (ABVX)